Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase 4 1Phase 3 1

Status

Unknown 2Terminated 2Recruiting 2

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Breast 1

Conditions

Neoplasms 1Heart Failure 1Cardiotoxicity 1Breast Neoplasms 1

Interventions

Cisplatin 270Oxaliplatin 195Carboplatin 191Capecitabine 184Docetaxel 178apatinib 164Paclitaxel 163Bevacizumab 159Gemcitabine 156Radiotherapy 147camrelizumab 146Fluorouracil 144Cyclophosphamide 126Irinotecan 120Drug Therapy 120sintilimab 108Etoposide 99anlotinib 90S 1 (combination) 89pembrolizumab 86Leucovorin 86toripalimab 78Pemetrexed 78Doxorubicin 77tislelizumab 76Dexamethasone 71Trastuzumab 65Neoadjuvant Therapy 65Rituximab 62Cetuximab 62

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 2 × Unknown × Hydroxymethylglutaryl-CoA Reductase Inhibitors × Clear all
NCT03186404 2022-02-08

SPARE-HF

University Health Network, Toronto

Phase 2 Unknown
112 enrolled

Heart Failure, Neoplasms, Cardiotoxicity

NCT00914017 2010-02-11

Statins and Breast Cancer Biomarkers

University of Vermont

Phase 2 Unknown
100 enrolled
Breast

Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡